Biotech Values

[mcbio]

Now if NKTR-118 is intended for regular use by those taking opioids (who are prone to constipation) I think that is a bigger opportunity then use to induce a bowl movement.

I think either way both drugs are addressing a large market. I am pretty sure that Salix previously disclosed during one of their CCs after they licensed Relistor rights that they believed that Relistor has the chance to be a >$1B/year drug assuming that the subQ version gets expanded approval in chronic, non-cancer patients and, most importantly, that the oral version also gets approved in this patient population. I searched through the archives here and have yet to find it but I seem to recall that. Don't hold me to it until and unless I find it. ; ) Doesn't mean it will happen of course but Salix seems to have a lot of confidence in Relistor and that seems to be borne out in the terms PGNX received on the deal ($60M up-front and 15-19% royalties on U.S. sales, among other terms). SLXP is no big pharma so that type of up-front is more consequential to a company of their size than it would be to a big pharma.